Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors

Onkologie

Volumn 30, Issue 7, 2007, Pages 361-366

  Kouvaris, J R ^a,b   Miliadou, A ^a   Kouloulias, V E ^a   Kolokouris, D ^a   Balafouta, M J ^a   Papacharalampous, X N ^b   Vlahos, L J ^a,b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Brain metastases; Radiotherapy; Temozolomide

Indexed keywords

ANTICONVULSIVE AGENT; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DRUG EFFICACY; FEMALE; HUMAN; LEUKOPENIA; LIVER TOXICITY; LUNG CANCER; MALE; MELANOMA; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; RECTUM CANCER; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASMS, UNKNOWN PRIMARY; PALLIATIVE CARE; RECTAL NEOPLASMS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 34347355387     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102557     Document Type: Article

References (35)

1. Posner JB: Management of brain metastases. Rev Neurol 1992;148:477-487.
2. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumours: the national survey of intracranial neoplasms. Neurology 1985;35:219-226.
3. Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 1978;19:579-592.
4. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI: Identification of prognostic factors in patients with brain metastases: a review of 1,292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.
5. Berk L: An overview of radiotherapy trials for the treatment of brain metastases. Oncology 1995;9: 1205-1219.
6. Mintz AH, Kestle J, Gaspar L, Hungenholtz H, Fisher B, Duncan G, Skingley P, Foster G, Levine M: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with single cerebral metastasis. Cancer 1996;78: 1470-1476.
7. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR: Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. Ann Neurol 1993; 33:583-590.
8. Schackert G: Surgery of brain metastases - pro and contra. Onkologie 2002;25:480-481.
9. Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 1980;7: 529-541.
10. Van der Steen-Banasik E, Hermans J, Tjho-Heslinga R, Caspers R, Leer JW: The objective response of brain metastases on radiotherapy. A prospective study using computer tomography. Acta Oncol 1992;31:777-780.
11. Van den Bent MJ: The role of chemotherapy in brain metastases. Eur J Cancer 2003;39:2114-2120.
12. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA: Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-imidazo[5,l-d]-1.2.3.5-tetrazin-4(3H)-one (CCRG 81045;M and B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987;47:5846-5852.
13. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES: In vitro evaluation of temozolomide combined with x-irradiation. Anticancer Drugs 1997;8:92-97.
14. Brandes AA, Pasetto LM, Vastola F, Monfardini S: Temozolomide in patients with high grade gliomas. Oncology 2000;59:181-186.
15. Combs SE, Gutwein S, Schulz-Ertner D, van Kampen M, Thilman C, Edler L, Wannenmacher MM, Debus J: Temozolomide combined with irradiation as postoperative treatment of primary glioblastoma multiforme. Phase I/II study. Strahlenther Onkol 2005;181:372-377.
16. Douglas JG, Margolin K: The treatment of brain metastases from malignant melanoma. Semin Oncol 2002;29:518-524.
17. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004;22:2101-2107.
18. Arbey LE, Christodoulou C: Temozolomide for treating brain metastases. Semin Oncol 2001;28(4 suppl 13):34-42.
19. Van den Bent MJ, Stupp R, Brandes AA, Lacombe D: Current and future trials of the EORTC brain tumor group. Onkologie 2004;27:246-250.
20. Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346.
21. Overgaard J, Bartelink H: Late effects consensus conference: RTOG/EORTC. Radiother Oncol 1995;35:1-82.
22. MacDonald DR, Cascino TL, Schold SC, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
23. Schultheiss TE, Kun LE, Ang KK, Stephens LC: Radiation response of the central nervous system. Int J Radiat Oncol Biol Phys 1995;31:1093-1112.
24. Landonio G, Sartore-Bianchi A, Giannetta L, Renga M, Riva M, Siena S: Controversies in the management of brain metastases: the role of chemotherapy. Forum (Genova) 2001;l:59-74.
25. Lee JS, Murphy WK, Glisson BS, Dhingra HM, Holoye PY, Hong WK: Primary chemotherapy of brain metastases in small-cell lung cancer. J Clin Oncol 1989;7:916-922.
26. Quantin X, Khial F, Reme-Saumon M, Michel FB, Pujol JL: Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer. Lung Cancer 1999;26:35-39.
27. Brock CS, Matthews JC, Brown G: Demonstration and quantitation of temozolomide uptake in vivo in human brain tumors. Ann Oncol 1996;7:137.
28. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Mara M, Abbruzzese A, Palmieri G, Budillon A, Grillone F, Venuta S, Tagliaferri P, Del Prete S: Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006;57:34-39.
29. Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M, Klouvas G, Skarlos D: Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Group (HeCOG) phase II study. J Neurooncol 2005;71: 61-65.
30. Stupp R, Dietrich PY, Ostermann Kraljevic S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20: 1375-1382.
31. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, Throuvalas N: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002;20:3644-3650.
32. Verger E, Gil M, Yaya R, Viñolas N, Villà S, Pujol T, Quintó L, Graus F: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomised trial. Int J Radiat Oncol Biol Phys 2005;61:185-191.
33. Gaspar LE, Scott C, Murray K, Curran W: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000;47:1001-1006.
34. Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, Guarrasi R, Caserta L, Del Prete S: Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer 2007;7:18.
35. Sheline GE, Wara WM, Smith V: Therapeutic irradiation and brain injury. Int J Radiat Oncol Biol Phys 1980;6:1215-1228.